Valentin Gonay, Michael P. Dunne, Javier Caceres‐Delpiano, Andrey V. Kajava
{"title":"Developing machine‐learning‐based amyloidogenicity predictors with Cross‐Beta DB","authors":"Valentin Gonay, Michael P. Dunne, Javier Caceres‐Delpiano, Andrey V. Kajava","doi":"10.1002/alz.14510","DOIUrl":null,"url":null,"abstract":"INTRODUCTIONThe importance of protein amyloidogenesis, associated with various diseases and functional roles, has driven the creation of computational predictors of amyloidogenicity. The accuracy of these predictors, particularly those utilizing artificial intelligence technologies, heavily depends on the quality of the data.METHODSWe built Cross‐Beta DB, a database containing high‐quality data on known cross‐β amyloids formed under natural conditions. We used it to train and benchmark several machine‐learning (ML) algorithms to predict amyloid‐forming potential of proteins.RESULTSWe developed the Cross‐Beta predictor using an Extra trees ML algorithm, which outperforms other amyloid predictors with the highest F1 score (0.852) and accuracy (0.844) compared to existing methods.DISCUSSIONThe development of the Cross‐Beta DB database and a new ML‐based Cross‐Beta predictor may enable the creation of personalized risk profiles for neurodegenerative diseases and other amyloidoses—especially as genome sequencing becomes more affordable.Highlights<jats:list list-type=\"bullet\"> <jats:list-item>Accuracy of ML‐based predictors depends on the quality of training data</jats:list-item> <jats:list-item>We built Cross‐Beta DB, a database of high‐quality data on naturally‐occurring amyloids</jats:list-item> <jats:list-item>Using this data, we developed an amyloid predictor that outperforms other predictors</jats:list-item> <jats:list-item>This computational tool enables the creation of risk profiles for neurodegenerative diseases</jats:list-item> </jats:list>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"35 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.14510","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTIONThe importance of protein amyloidogenesis, associated with various diseases and functional roles, has driven the creation of computational predictors of amyloidogenicity. The accuracy of these predictors, particularly those utilizing artificial intelligence technologies, heavily depends on the quality of the data.METHODSWe built Cross‐Beta DB, a database containing high‐quality data on known cross‐β amyloids formed under natural conditions. We used it to train and benchmark several machine‐learning (ML) algorithms to predict amyloid‐forming potential of proteins.RESULTSWe developed the Cross‐Beta predictor using an Extra trees ML algorithm, which outperforms other amyloid predictors with the highest F1 score (0.852) and accuracy (0.844) compared to existing methods.DISCUSSIONThe development of the Cross‐Beta DB database and a new ML‐based Cross‐Beta predictor may enable the creation of personalized risk profiles for neurodegenerative diseases and other amyloidoses—especially as genome sequencing becomes more affordable.HighlightsAccuracy of ML‐based predictors depends on the quality of training dataWe built Cross‐Beta DB, a database of high‐quality data on naturally‐occurring amyloidsUsing this data, we developed an amyloid predictor that outperforms other predictorsThis computational tool enables the creation of risk profiles for neurodegenerative diseases
期刊介绍:
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.